Drew M. Pardoll
Johns Hopkins University
4 papers in the Anchorcite directory, published between 2012 and 2017, cited 37,145 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 4 papers
- Immunotherapy and Immune Responses · 3 papers
- T-cell and B-cell Immunology · 2 papers
- Genetic factors in colorectal cancer · 2 papers
- Colorectal Cancer Treatments and Studies · 1 paper
Frequent co-authors
- Robert A. Anders · 3 papers
- Janis Marie Taube · 3 papers
- Suzanne Louise Topalian · 2 papers
- Julie Renee Brahmer · 2 papers
- Charles G. Drake · 2 papers
- Alan J. Korman · 2 papers
- Ashok Kumar Gupta · 2 papers
- Jon M. Wigginton · 2 papers
Papers
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine · 2012 · 12,793 citations
BACKGROUND: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1. METHODS: We enrolled patients with advanced melanoma,…
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine · 2015 · 9,526 citations
BACKGROUND: Somatic mutations have the potential to encode "non-self" immunogenic antigens. We hypothesized that tumors with a large number of somatic mutations due to mismatch-repair defects may be susceptible to immune checkpoint blockade. METHODS: We conducted a phase 2 study…
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine · 2012 · 8,054 citations
BACKGROUND: Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host's immune system. Blockade of interactions between PD-1 and PD-L1 enhances…
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience · 2017 · 6,772 citations
The genomes of cancers deficient in mismatch repair contain exceptionally high numbers of somatic mutations. In a proof-of-concept study, we previously showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death…
Metadata from OpenAlex (CC0).